Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

Bacillus Calmette-Guérin (BCG) Tice, the active ingredient in Oncotice, is a live‑attenuated bacterial immunotherapy presented as a suspension for intravesical use. It is employed in the treatment of non‑muscle‑invasive bladder cancer, primarily in patients who have undergone transurethral resection of the tumour. GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres and hospitals worldwide.

Oncotice is a live‑attenuated bacterial immunotherapy used within the uro‑urological pathway.

- Non‑muscle‑invasive bladder cancer: reduces recurrence and progression after tumour resection. - Carcinoma in situ of the bladder: induces local immune response to eradicate malignant cells. - High‑risk papillary tumours: provides adjuvant therapy to lower the chance of disease recurrence.

Oncotice may elicit a range of local and systemic reactions following intravesical administration.

Common Side Effects: - Mild urinary irritation: burning  or  pain  during  void  or  frequency. - Low‑grade fever  and  chills  within  24  hours. - Hematuria  or  blood  in  urine  that  resolves  spontaneously. - Dysuria  or  pain  during  micturition. - Transient fatigue  or  malaise  after  instillation.

Serious or Rare Side Effects: - Systemic BCG infection (disseminated mycobacterial disease). - Severe allergic reaction or anaphylaxis. - Persistent high‑grade fever lasting  >  48  hours. - Acute renal  injury  or  obstructive  uropathy  due  to  edema  of  the  prostate  or  bladder neck. - Sepsis sepsis  of  the  urinary  tract  or  bloodstream  infection  with  BC  ​  .

Oncotice requires careful clinical oversight during treatment.

- Assess  for  active  tuberculosis  or  latent  TB  infection  before  administration. - Evaluate  immune  status  and  avoid  use  in  severely  immunocompromised  patients  (e.g., HIV  with  CD4  <  200). - Monitor  renal  function  and  urinary  tract  obstruction  before  each  instillation. - Conduct  cystoscopic  evaluation  prior  to  each  treatment  session  ​  . - Store at  2‑                    """"  "  " " " " "  ""  ""  "" "  "  "